BBH241115C166000
- 0.00
- 0.000.00%
VanEck Biotech ETF Newsroom
AstraZeneca's China Business Under Spotlight Amid Fraud Case
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Arcus Says Gilead-partnered Cancer Therapy Cut Death Risk by 36%
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
10 Health Care Stocks Whale Activity In Today's Session
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
Peering Into IQVIA Hldgs's Recent Short Interest
JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $240
JP Morgan Maintains Neutral on Illumina, Raises Price Target to $140
Vertex Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Issued FY24 Product Revenue Guidance Above Estimates. Also, Morgan Stanley Maintained an Equal-Weight Rating on the Stock and...
Arcellx Issues Updates on Anito-cel Clinical Trials
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
This EBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Gilead Sciences's Earnings: A Preview
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Vertex Pharmaceuticals Analyst Ratings
Illumina Analyst Ratings
Vertex Raises 2024 Product Revenue Outlook Following Q3 Beats
Illumina Stock Falls 6% Amid Lowered 2024 Revenue Guidance